These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 25948423)

  • 1. Is sunitinib-induced hypothyroidism a predictive clinical marker for better response in metastatic renal cell carcinoma patients?
    Bozkurt O; Karaca H; Hacıbekiroglu I; Kaplan MA; Duzkopru Y; Uysal M; Berk V; Inanc M; Duran AO; Ozaslan E; Ucar M; Ozkan M
    J Chemother; 2016 Jun; 28(3):230-4. PubMed ID: 25948423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does sunitinib-induced hypothyroidism play a role in the activity of sunitinib in metastatic renal cell carcinoma?
    Sella A; Hercbergs AH; Hanovich E; Kovel S
    Chemotherapy; 2012; 58(3):200-5. PubMed ID: 22759787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypothyroidism in patients with renal cell carcinoma: blessing or curse?
    Schmidinger M; Vogl UM; Bojic M; Lamm W; Heinzl H; Haitel A; Clodi M; Kramer G; Zielinski CC
    Cancer; 2011 Feb; 117(3):534-44. PubMed ID: 20845482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sunitinib-induced hypothyroidism predicts progression-free survival in metastatic renal cell carcinoma patients.
    Buda-Nowak A; Kucharz J; Dumnicka P; Kuzniewski M; Herman RM; Zygulska AL; Kusnierz-Cabala B
    Med Oncol; 2017 Apr; 34(4):68. PubMed ID: 28343336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ιmpact of sunitinib-induced hypothyroidism on survival of patients with metastatic renal cancer.
    Vasileiadis T; Chrisofos M; Safioleas M; Kontzoglou K; Papazisis K; Sdrolia A
    BMC Cancer; 2019 Apr; 19(1):407. PubMed ID: 31039771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sunitinib-induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma.
    Rautiola J; Donskov F; Peltola K; Joensuu H; Bono P
    BJU Int; 2016 Jan; 117(1):110-7. PubMed ID: 25252180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of sunitinib-induced hypothyroidism on progression-free survival of metastatic renal cancer patients: a prospective single-center study.
    Baldazzi V; Tassi R; Lapini A; Santomaggio C; Carini M; Mazzanti R
    Urol Oncol; 2012 Sep; 30(5):704-10. PubMed ID: 20884255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Could thyroid dysfunction influence outcome in sunitinib-treated metastatic renal cell carcinoma?
    Sabatier R; Eymard JC; Walz J; Deville JL; Narbonne H; Boher JM; Salem N; Marcy M; Brunelle S; Viens P; Bladou F; Gravis G
    Ann Oncol; 2012 Mar; 23(3):714-721. PubMed ID: 21653681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib.
    Riesenbeck LM; Bierer S; Hoffmeister I; Köpke T; Papavassilis P; Hertle L; Thielen B; Herrmann E
    World J Urol; 2011 Dec; 29(6):807-13. PubMed ID: 21153827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is Late Recurrence a Predictive Clinical Marker for Better Sunitinib Response in Metastatic Renal Cell Carcinoma Patients?
    Bozkurt O; Hacıbekiroglu I; Kaplan MA; Duzkopru Y; Uysal M; Karaca H; Berk V; Inanc M; Duran AO; Ozaslan E; Ucar M; Ozkan M
    Clin Genitourin Cancer; 2015 Dec; 13(6):548-54. PubMed ID: 26320661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of progression-free survival as a surrogate end-point for overall survival in patients with metastatic renal cell carcinoma.
    Négrier S; Bushmakin AG; Cappelleri JC; Korytowsky B; Sandin R; Charbonneau C; Michaelson MD; Figlin RA; Motzer RJ
    Eur J Cancer; 2014 Jul; 50(10):1766-1771. PubMed ID: 24768571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib.
    Keizman D; Sarid D; Lee JL; Sella A; Gottfried M; Hammers H; Eisenberger MA; Carducci MA; Sinibaldi V; Neiman V; Rosenbaum E; Peer A; Neumann A; Mermershtain W; Rouvinov K; Berger R; Yildiz I
    Oncologist; 2016 Oct; 21(10):1212-1217. PubMed ID: 27382030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypothyroidism as a predictive clinical marker of better treatment response to sunitinib therapy.
    Kust D; Prpić M; Murgić J; Jazvić M; Jakšić B; Krilić D; Bolanča A; Kusić Z
    Anticancer Res; 2014 Jun; 34(6):3177-84. PubMed ID: 24922691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does the onset of bone metastasis in sunitinib-treated renal cell carcinoma patients impact the overall survival?
    Ivanyi P; Koenig J; Trummer A; Busch JF; Seidel C; Reuter CW; Ganser A; Grünwald V
    World J Urol; 2016 Jul; 34(7):909-15. PubMed ID: 26586475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of sunitinib-associated macrocytosis in metastatic renal cell carcinoma.
    Bourlon MT; Gao D; Trigero S; Clemons JE; Breaker K; Lam ET; Flaig TW
    Cancer Med; 2016 Dec; 5(12):3386-3393. PubMed ID: 27758076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperlipidemia and hypothyroidism among metastatic renal cell carcinoma patients taking sunitinib malate. Related or unrelated adverse events?
    Tassi R; Baldazzi V; Lapini A; Carini M; Mazzanti R
    Clin Genitourin Cancer; 2015 Apr; 13(2):e101-5. PubMed ID: 25450040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma.
    Elfiky AA; Cho DC; McDermott DF; Rosenberg JE; Fortner B; Antràs L; Chen K; Sheng Duh M; Jayawant SS; Oh WK; Atkins MB; Choueiri TK
    Urol Oncol; 2011; 29(6):756-63. PubMed ID: 20451414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma.
    Diekstra MH; Swen JJ; Boven E; Castellano D; Gelderblom H; Mathijssen RH; Rodríguez-Antona C; García-Donas J; Rini BI; Guchelaar HJ
    Eur Urol; 2015 Oct; 68(4):621-9. PubMed ID: 25930089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Standard vs adapted sunitinib regimen in elderly patients with metastatic renal cell cancer: results from a large retrospective analysis.
    De Giorgi U; Scarpi E; Sacco C; Aieta M; Lo Re G; Sava T; Masini C; De Vincenzo F; Baldazzi V; Camerini A; Fornarini G; Burattini L; Rosti G; Ferrari V; Moscetti L; Chiuri VE; Luzi Fedeli S; Amadori D; Basso U
    Clin Genitourin Cancer; 2014 Jun; 12(3):182-9. PubMed ID: 24369790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On-target Toxicities Predictive of Survival in Metastatic Renal Cell Carcinoma (mRCC) Treated With Sunitinib: A Multicenter Retrospective Study.
    Bolzacchini E; Pinotti G; Bertù L; Verusio C; Galli L; Mumoli N; Barbara C; Danova M; Bregni M; Artale S; Rossini C; Nigro O; Antonuzzo A; Derosa L; Torchio M; Barzaghi S; Ricci I; Suter M; Ballerio A; Vallini I; Dentali F
    Clin Genitourin Cancer; 2020 Apr; 18(2):e145-e156. PubMed ID: 31889670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.